Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + pembrolizumab + pemetrexed + carboplatin
- Development stage
- Phase 3
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenvatinib + pembrolizumab + pemetrexed + carboplatin is an investigational four-drug combination regimen developed by Eisai and Merck & Co. for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). The regimen combines lenvatinib (a multi-kinase inhibitor targeting VEGFR and FGFR), pembrolizumab (an anti-PD-1 monoclonal antibody), and a chemotherapy backbone of pemetrexed and carboplatin. The combination was designed to enhance anti-tumor activity by simultaneously targeting angiogenesis, immune evasion, and cellular proliferation. However, the Phase 3 LEAP-006 trial (NCT03829319) demonstrated that the addition of lenvatinib to the pembrolizumab plus chemotherapy standard-of-care did not provide a survival benefit, leading to the termination of this specific combination's development for this indication.
- Other names
- lenvatinib mesylatepembrolizumabpemetrexed disodiumcarboplatin
02
Targets
DNADHFR (Dihydrofolate reductase)FGFR1 (Fibroblast growth factor receptor 1)GART (GAR transformylase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + pembrolizumab + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + pembrolizumab + pemetrexed + carboplatin.